Skip to main content

Recombinant Mouse FGF-23 Protein, CF

Bio-Techne includes R&D Systems | Catalog # 2629-FG/CF

Catalog #
Availability
Size / Price
Qty
Loading...
2629-FG-025/CF

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived mouse FGF-23 protein
Tyr25-Val251 (Arg179Gln), with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Tyr25

Predicted Molecular Mass

26.1 kDa

SDS-PAGE

30-32 kDa, reducing conditions

Activity

Measured in a cell proliferation assay using BaF3 mouse pro-B cells transfected with human FGF RIIIc.
The ED50 for this effect is 0.2‑1.2 µg/mL in the presence of Recombinant Mouse Klotho (Catalog # 1819-KL) and heparin.

Formulation, Preparation and Storage

2629-FG/CF
Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, Na2SO4, EDTA and DTT.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: FGF-23

Fibroblast growth factor 23 (FGF-23) is a 30 - 32 kDa member of the FGF gene family. Based on its structure, it is further classified as an FGF19 subfamily member. This subfamily includes FGF-19, -21, and -23. Like all other FGF subfamilies, FGF-19 subfamily members contain a 120 amino acid (aa) core FGF domain that exhibits a beta-trefoil structure (1, 2). Unlike other FGF subfamilies, FGF-19 subfamily members exist as highly diffusible molecules that is attributed to poor ECM/heparin sulfate binding (3, 4, 5, 6). The cDNA for mouse FGF-23 predicts a 251 aa polypeptide that contains a 24 aa signal sequence and a 227 aa mature region (7). Mature mouse FGF-23 shows 72% aa identity to human FGF-23 (8). The FGF-19 subfamily shares an unusual receptor configuration. The standard model for FGF signaling requires an FGF:FGFR:heparin sulfate complex. Given FGF-23’s minimal association with heparin, a substitute termed ( alpha-) Klotho has evolved that serves the same function. Although FGF-23 binds to the widely expressed “c” isoforms of FGFR1 and 3 plus FGFR4, Klotho has a restricted distribution that limits FGF-23 activity (10, 11, 12). It should be noted that heparin-dependency has been reported for FGF-19 signaling, and this observation may extend to FGF-23 (13). The FGF-19 subfamily is considered endocrine in nature. All three subfamily members impact some aspect of metabolism and all three are induced by a nuclear receptor heterodimer that includes the retinoid X receptor (14, 15, 16). FGF-23 is considered a phosphatonin; that is, a molecule that reduces circulating plasma phosphate. It is produced by osteocytes and osteoblasts in response to high circulating phosphate levels, elevated parathyroid hormone that induces hypercalcemia, and circulatory volume loading. Upon binding to FGF-23 receptors on renal proximal tubular epithelium, two basic changes are seen. First, the enzyme responsible for generating the active form of vitamin D is suppressed, resulting in decreased levels of bioactive vitamin D. Since vitamin D promotes intestinal phosphate absorption, plasma phosphate declines. Second, the transporters responsible for phosphate resorption on renal epithelium are down regulated, resulting in decreased uptake from urine and again a decline in blood phosphorus (17, 18).

References

  1. Itoh, N. and D.M. Ornitz (2004) Trends Genet. 20:563. 
  2. Mohammadi, M. et al. (2005) Cytokine Growth Factor Rev. 16:107.
  3. Fukumoto, S. (2007) Endocr. J. Sep 14; [Epub ahead of print].
  4. Huang, X. et al. (2006) Mol. Carcinog. 45:934. 
  5. Goetz, R. et al. (2007) Mol. Cell. Biol. 27:3417.
  6. Harmer, N.J. et al. (2004) Biochemistry 43:629.
  7. Yamashita, T. et al. (2000) Biochem. Biophys. Res. Commun. 277:494.
  8. Shimada, T. et al. (2001) Proc. Natl. Acad. Sci. USA 98:6500.
  9. Kato, K. et al. (2006) J. Biol. Chem. 281:18370.
  10. Zhang, X. et al. (2006) J. Biol. Chem. 281:15694.
  11. Urakawa, I. et al. (2006) Nature 444:770.
  12. Hurosu, H. et al. (2006) J. Biol. Chem. 281:6120.
  13. Wu, X. et al. (2007) J. Biol. Chem. 282:29069.
  14. Moore, D.D. (2007) Science 316:1436.
  15. Ogawa, Y. et al. (2007) Proc. Natl. Acad. Sci. USA 104:7432.
  16. Kurosu, H. et al. (2007) J. Biol. Chem. 282:26687.
  17. Razzaque, M.S. and B. Lanske (2007) J. Endocrinol. 194:1.
  18. Liu, S. et al. (2007) Curr. Opin. Nephrol. Hypertens. 16:329.

Long Name

Fibroblast Growth Factor 23

Alternate Names

FGF23

Entrez Gene IDs

8074 (Human); 64654 (Mouse)

Gene Symbol

FGF23

UniProt

Additional FGF-23 Products

Product Documents for Recombinant Mouse FGF-23 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Mouse FGF-23 Protein, CF

For research use only

Loading...
Loading...
Loading...